科研动态PubMed 摘要

阿泽图卡纳治疗成人局灶性癫痫发作:X-TOLE2 3期随机临床试验。

PubMed 白名单日捞 · 2026-11-09

完整摘要 · 中文译文

重要性:尽管已有30多种获批的抗癫痫发作药物,许多局灶性癫痫患者仍继续出现癫痫发作,这表明对新疗法的持续需求。 目的:确定新型、强效KV7通道开放剂azetukalner治疗局灶性发作的疗效和安全性。 设计、设置和参与者:这项azetukalner的3期、安慰剂对照随机临床试验在12周双盲期内(2022年11月18日至2026年2月3日)于北美、南美、欧洲和亚太地区的138个中心开展。纳入尽管接受1至3种抗癫痫发作药物稳定治疗但每月仍出现4次或以上局灶性发作的成人局灶性癫痫患者。数据分析使用来自2026年2月26日数据库锁定的数据集。 干预:参与者按1:1:1随机分配接受安慰剂或15 mg或25 mg azetukalner,每晚随餐每日一次,持续12周,无滴定期。完成双盲期的参与者可进入开放标签扩展期。 主要结局和指标:主要疗效终点为双盲期内azetukalner与安慰剂相比每月(28天)局灶性发作频率较基线的中位百分比变化。安全性和耐受性通过记录治疗中出现的不良事件、临床实验室检查结果变化、生命体征和心电图进行评估。 结果:在筛选的607名成人中,374名参与者(190名[50.8%]女性;平均[SD]年龄,40.0[12.9]岁)被纳入、随机化并接受治疗 安慰剂(125名受试者)、15 mg azetukalner(125名受试者)或25 mg azetukalner(124名受试者)。受试者基线每月癫痫发作次数的中位数(IQR)为12.75(7.56至32.97)次,既往曾尝试并停用的抗癫痫药物中位数(IQR)为5(3至8)种。大多数(336名受试者[89.8%])正在接受2至3种合并抗癫痫药物治疗。每月癫痫发作频率较基线的中位数(IQR)变化为:安慰剂组-10.4%(-39.1%至8.3%),15 mg azetukalner组-34.5%(-61.6%至-12.3%)(与安慰剂相比P < .001),25 mg azetukalner组-53.2%(-77.2%至-28.8%)(与安慰剂相比P < .001)。azetukalner总体耐受性良好,治疗中出现的不良事件与2b期X-TOLE试验中观察到的相当。 结论与意义:这项随机临床试验发现,azetukalner在癫痫发作频率方面表现出稳健、快速且持久的降低,并具有良好的获益-风险特征。在药物难治性癫痫患者中,azetukalner治疗实现了迄今报道的与安慰剂相比最大的癫痫发作频率中位百分比降低之一,支持azetukalner作为一种有前景的新型抗癫痫药物,具有显著改善临床结局的机会。 试验注册:ClinicalTrials.gov标识符:NCT05614063。

完整摘要 · 英文原文

IMPORTANCE: Despite more than 30 approved antiseizure medications, many individuals with focal epilepsy continue to experience seizures, indicating a persistent need for novel therapies. OBJECTIVE: To determine efficacy and safety of the novel, potent KV7 channel opener azetukalner for treatment of focal seizures. DESIGN, SETTING, AND PARTICIPANTS: This phase 3, placebo-controlled randomized clinical trial of azetukalner was conducted over a 12-week double-blind period (November 18, 2022, to February 3, 2026) at 138 sites in North America, South America, Europe, and Asia Pacific. Adults with focal epilepsy experiencing 4 or more focal seizures per month despite stable treatment with 1 to 3 antiseizure medications were enrolled. Data were analyzed using a dataset derived from the database lock dated February 26, 2026. INTERVENTIONS: Participants were randomized 1:1:1 to receive placebo or 15 or 25 mg of azetukalner once daily with the evening meal for 12 weeks with no titration period. Participants completing the double-blind period could enter an open-label extension. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was median percentage change from baseline in monthly (28-day) focal seizure frequency during the double-blind period for azetukalner vs placebo. Safety and tolerability were assessed by recording treatment-emergent adverse events, changes in clinical laboratory findings, vital signs, and electrocardiogram. RESULTS: Of 607 adults screened, 374 participants (190 [50.8%] female; mean [SD] age, 40.0 [12.9] years) were enrolled, randomized and treated with placebo (125 participants), 15-mg azetukalner (125 participants), or 25-mg azetukalner (124 participants). Participants had a baseline median (IQR) of 12.75 (7.56 to 32.97) seizures per month and had previously tried and stopped a median (IQR) of 5 (3 to 8) antiseizure medications. Most (336 participants [89.8%]) were receiving 2 to 3 concomitant antiseizure medications. The median (IQR) change from baseline in monthly seizure frequency was -10.4% (-39.1% to 8.3%) for the placebo group, -34.5% (-61.6% to -12.3%) for the 15-mg azetukalner group (P < .001 vs placebo), and -53.2% (-77.2% to -28.8%) for the 25-mg azetukalner group (P < .001 vs placebo). Azetukalner was generally well tolerated, and treatment-emergent adverse events were comparable to those observed in the phase 2b X-TOLE trial. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that azetukalner demonstrated robust, rapid, and durable reductions in seizure frequency with a favorable benefit-risk profile. Treatment with azetukalner resulted in one of the largest median percentage reductions in seizure frequency vs placebo reported to date in patients with drug-resistant epilepsy, supporting azetukalner as a promising novel antiseizure medication with significant opportunity to improve clinical outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05614063.

English
Azetukalner in Adults With Focal Seizures: The X-TOLE2 Phase 3 Randomized Clinical Trial.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界